US panel gives review date for FS069:
This article was originally published in Clinica
Executive Summary
The US FDA's Radiology Devices Advisory Panel will review Molecular Biosystems' ultrasound contrast agent FS069 on February 24th. The company has applied for approval in 2D echocardiography procedures and plans to seek subsequent approvals for myocardial perfusion and enhancement of liver and kidney imaging.